MicroRNAs (miRNAs) are a novel class of small noncoding RNA molecules that regulate gene expression by inducing degradation or translational inhibition of target mRNAs. There are more than 500 miRNA genes reported in the human genome, constituting one of the largest classes of regulatory genes. Increasing experimental evidence supports the idea of aberrant miRNA expression in cancer pathogenesis. We analyzed the pattern of miRNA expression in chronic lymphocytic leukemia (CLL) cells and our results showed a global reduction in miRNA expression levels in CLL cells associated to a consistent underexpression of miR-181a, let-7a and miR-30d. We observed overexpression of miR-155 and a set of five miRNAs that are differentially expressed between patients with different clinical outcomes. Five novel miRNA candidates cloned from leukemic cells are reported. Surprisingly, predicted mRNA targets for these novel miRNA revealed a high proportion of targets located in a small region of chromosome 1, which is frequently altered in human cancer. Additionally, several targets were shared by at least two of miRNA candidates. Predicted targets included several genes recently described as tumor suppressors. These data could afford new avenues for exploring innovative pathways in CLL biology and therapy.
Introduction
B-chronic lymphocytic leukemia (CLL), the commonest leukemia of Western countries 1 is characterized by elevated numbers of circulating clonal leukemic B cells. It was classically considered as resulting from accumulation of minimally selfrenewing B cells as a consequence of defective apoptosis. 2, 3 Most peripheral CLL cells are typically in G 0 /G 1 tending to be kinetically resting, phenotypically activated and functionally anergic with reduced levels of the B-cell antigen receptor components IgM, IgD and CD79b with most malignant B cells over expressing the antiapoptotic B-cell lymphoma 2 (Bcl-2) protein. [4] [5] [6] However, recent evidence indicates that CLL is not a static disease that results simply from accumulation of long-lived lymphocytes, but as a dynamic process in which cells proliferate and die, often at appreciable levels. 7 CLL shows a highly variable clinical course spanning from rapidly aggressive to completely indolent behaviors. 5 Several biological markers have been described that can predict the clinical course and are useful to segregate patients into two main groups according to the mutational status of the immunoglobulin heavy-chain variable-region gene (IgV H ), the expression levels of the ZAP-70 tyrosine kinase and CD38 þ expression, [8] [9] [10] [11] as well as the presence of cytogenetic abnormalities, such as 11q or 17p deletions. 12 Patients with clones having unmutated (NM) IgV H genes or with high expression of either CD38 or ZAP-70 and/or 11q or 17p deletions have frequently a rapidly fatal course despite aggressive therapy, whereas patients with mutated (M) clones or low CD38 or ZAP-70 expression and no deleterious cytogenetic abnormalities have an indolent course and frequently die by unrelated diseases. Despite recent advances in CLL biology the molecular mechanism involved in its initiation and progression remains elusive. Recently, a novel class of small noncoding RNAs dubbed microRNAs (miRNAs) have been identified in plants and animals. 13, 14 Mature miRNAs of 19-24 nt in length regulate target gene expression posttranscriptionally through base pairing within 3 0 -UTR regions of the target messenger RNAs inducing the degradation and/or translational inhibition. 13, 15 Although the biological functions of miRNAs are not yet fully understood, it has been demonstrated that they participate in the regulation of developmental timing, cell death, cell proliferation, fat metabolism, hematopoiesis and patterning of the nervous system. 16 The finding that more than half of the known human miRNAs are located at cancerassociated regions of the genome suggested that miRNAs might play a broad role in cancer pathogenesis. 17 Consistent with this notion is the observed aberrant expression of miRNAs in diverse cancer subtypes, including Burkitt's lymphoma, 18 colorectal cancer, 19 lung cancer, 20 breast cancer 21 and glioblastoma. 22 Increasing experimental evidence implicates miRNAs either as oncogenes or tumor suppressors. [23] [24] [25] [26] Recently, two different strategies were used to profile miRNA expression in CLL. 27, 28 By a microarray approach a specific expression signature consisting of 13 miRNAs, including miR-15a and miR-16, was associated with relevant prognostic factors. 29 Following the report of bcl-2 as a physiological target of these two miRNAs, 30 a role of miR15a and miR-16 in CLL pathogenesis was also proposed through the upregulation of bcl-2. However, recent reports revealed that significant reduction in miR-15 and/or miR-16 expression levels in CLL was not paralleled by any significant change in bcl-2.
28
In another recent study using a cloning-based strategy, the aberrant expression profile of miRNAs in CLL showed that miR-21, miR-150 and miR-155 were significantly overexpressed. 28 Microarray methods are powerful for global analysis but they have technical limitations when used with miRNAs due to their short size and the sequence similarity between family members. Additionally and most importantly, microarray studies are directed toward reported miRNAs, excluding the analysis of unannotated candidates. Therefore, to gain insight into the role of miRNAs in CLL, we used a cloning-based approach combined with stringent northern blot assays to study small RNAs from CLL patients. Our results show the global fluctuation of miRNA expression levels in CLL cells compared to normal B cells and the identification of five novel miRNA candidates from CLL cells. The observed changes are associated with significant overexpression of miR-155 in combination with a reduction of miR-181a, let-7a and miR-30d. Notably, the differential profile of miRNA expression is associated with molecular prognostic factors and clinical course in CLL.
Materials and methods

B-lymphocyte purification from CLL patients and healthy donors
Samples from CLL patients and healthy donors were provided by the Hematology and Bone Marrow Transplantation Unit of the Hospital Maciel (Montevideo, Uruguay) and by the National Blood Bank, (Montevideo, Uruguay), respectively, after obtaining informed consent according to locally approved regulations. Peripheral blood mononuclear cells (PBMCs) were isolated by centrifugation over a Ficoll-Metrizoate density gradient from peripheral venous blood samples. CLL lymphocytes were further purified from PBMCs by negative selection using magnetic beads (Dynabeads, Invitrogen, Montevideo, Uruguay) coated with MoAbs according to the manufacturer's instructions, resulting in an enriched population containing more than 95% CD5 þ B cells. Samples from CLL patients were segregated according to the mutational status of IgV H genes, into NM and M groups.
Cloning of small RNAs
Cloning of small RNAs was performed from pooled samples belonging to three different patients corresponding respectively to the NM and the M groups as defined above. Total RNA as initial source for cloning small RNAs was extracted with the Trizol reagent (Invitrogen). Cloning was performed as described by Pfeffer et al. 31 with minor modifications from 400 mg of total RNA. Briefly, small RNAs between 18 and 26 bases were size selected on a 15% denaturing polyacrylamide gel. Unlabeled DNA size markers were used instead of radiolabeled RNA. At the end of electrophoresis the lane containing DNA size markers was excised and stained with ethidium bromide. The stained lane was then aligned with the gel and bands were excised according to the mobility of the DNA markers. After the inclusion of 5 0 and 3 0 adapters containing Ban I restriction sites and amplification by PCR, Ban I-digested PCR products were concatamerized and cloned into pGEM T-easy (Promega Corp., Buenos Aires, Argentina) according to the manufacturers' instructions. Colonies were screened using PCR and M13 sequencing primers. PCR products were directly submitted for custom sequencing. Sequence analysis and annotation were performed using information obtained from the public databases GenBank (http://www.ncbi.nlm.nih.gov/ Genbank/index.html) and miRBase (http://microrna.sanger.ac.uk/ sequences/index.shtml).
Northern blot analysis
A total of 30 mg of total RNA was run on a 15% denaturing polyacrylamide gel in 0.5 Â Tris-Borate-EDTA running buffer. Prior to transfer, gels were stained with ethidium bromide to verify equal loading. The RNA was electrophoretically transferred to GeneScreen Plus (Schleicher and Schuell, NH, USA). After transfer, membranes were cross-linked with 120 mJ of UV (Stratagene, GE Healthcare, Buenos Aires, Argentina) and baked at 80 1C for 1 h. Oligonucleotide probes were generated by T4 polynucleotide kinase-mediated end labeling (New England Biolabs, Beverly, MA, USA) using [ 32 P]g-ATP (end-labeling grade, 47000 Ci mmol À1 ; MP Biomedicals, Illkirch, Strasbourg, France) and were purified from unincorporated label with G-25 microspin columns. Filters were prehybridized at 40 1C in modified Church's buffer (5% sodium dodecyl sulfate (SDS), 0.5% nonfat dry milk, 1 mM EDTA in sodium phosphate buffer 0.25 M, pH 7.2). After prehybridization for 2 h, radiolabeledspecific probes were added and further incubated for 1 h. Membranes were washed twice at 42 1C with 2 Â sodium chloride/sodium citrate buffer (SSC) 0.1% SDS for 20 min, 1 Â SSC 0.1% SDS for 20 min and 0.5 Â SSC 0.1% SDS for 20 min. The hybridized membranes were exposed overnight to Kodak Biomax MS X-ray films. Hybridized probes were stripped from blots by washing twice in hot 0.1% SDS in deionized water for 15 min and reprobed up to three times.
Real-time RT-PCR analysis of precursor miRNAs
For cDNA synthesis 1 mg of total RNA was reverse transcribed with Superscript II reverse transcriptase (Invitrogen) using random hexamers (Invitrogen) to prime first-strand synthesis under conditions suggested by manufacturers. Quantitative PCR (qPCR) was perfomed in a LightCycler 2.0 System (Roche Applied Science, Meylan, Grenoble, France) using 1 ml of cDNA in 20 ml reaction volume with 0.4 mM of each specific primer and 2 ml of 10Â FastStar DNA Master SYBR Green I (Roche Molecular Biochemicals, Meylan, Grenoble, France) according to the manufacturer's instructions. Primers were designed according to the flanking sequences of mature miRNAs (premiRNAs), which amplify pre-miRNAs as well as primary transcripts of miRNAs (pri-miRNAs): 5S rRNA TACGGCCAT ACCACCCTG (forward) and GTACTAACCAGGCCCGACC (reverse); pre-let-7a-1 GGGATGAGGTAGTAGGTTGTATAG (forward) and TGGGATGAGGTAGTAGGTTGTATAG (reverse); pre-miR-16-1 GTCAGCAGTGCCTTAGCAGC (forward) and CAACCTTACTTCAGCAGCACAG (reverse); pre-miR-30d GTTG TTGTAAACATCCCCGAC (forward) and GTAGCAGCAAACATC TGACTGAA (reverse); pre-miR-142 GACAGTGCAGTCACCCA TAAAG (forward) and CACAGTACACTCATCCATAAAGTAGG (reverse); pre-miR-155 TGTTAATGCTAATCGTGATAGGGG (forward)) and TGCTAATATGTAGGAGTCAGTTGG (reverse); pre-miR-181a GAAGGGCTATCAGGCCAGC (forward) and CC CCAAGGTACAGTCAACG (reverse). The following program conditions were applied for qPCR running: denaturation program at 95 1C for 10 min, amplification and quantification program consisting 40 cycles (95 1C for 10 s, 60 1C for 10 s and 72 1C for 10 s). The relative amount of each precursor miRNA to the reference 5S rRNA gene was calculated using the following equation 32 and expressed as n-fold variation of miRNA levels in test samples (CLL cells) with respect to control samples (normal lymphocytes). Ratio ¼ (E target)DC t target (control sample)
/(E ref)DC t ref (control sample)
. Efficiencies (E) of each gene were calculated from the slopes of crossover points vs DNA concentration plot, according to the formula E ¼ 10
. PCR specificity was checked by melting curves. Agarose gel electrophoresis was used to verify the amplification of a unique band in order to validate qPCR assays. In all cases the identity of amplicons was verified by sequencing.
Prediction of miRNA targets
Putative targets for novel miRNAs candidates were predicted using the online (http://www.microrna.org/mammalian/ index.html) 'miRanda' algorithm. 33 For each novel miRNA, target genes were selected on the basis of sequence complementarity using a position-weighted local alignment algorithm associated to free energies (thermodynamic stability) of RNA-RNA duplexes. We selected the best 10 scores of targets for each miRNA as the most suitable candidates. We also used the TargetScan algorithm 34 to predict miRNAs biological targets by searching for the presence of nonconserved 8mer and 7mer sites that match the seed region of novel miRNAs (http://www. targetscan.org/).
Results
Cloning of small RNAs from CLL cells
As described, cloning of small RNAs was performed separately in pooled samples from 'M' and 'NM' groups of patients. The pooled samples from patients with indolent course (M) had mutated IgV H genes and were negative for ZAP-70. In contrast, the pooled samples from patients with a more aggressive clinical course (NM) were selected for having unmutated IgV H genes and more than 30% of leukemic cells positive for ZAP-70. A total of 237 clones obtained from the NM group and 287 clones obtained from the M group were sequenced and public database searching was performed to identify genomic sequences encoding the cloned fragments. The obtained clones were classified according to function based on sequence identity (Table 1) . Annotated miRNAs represented 24 out of 237 (B10%) and 32 out of 287 (B11%) small RNAs cloned from NM and M samples, respectively. The small RNAs sequenced included breakdown products of rRNA, snoRNA tRNA, snRNA and mitRNA, which represented more than half of total small RNA cloned for both samples. Sequences not matching the human genome (NDE in Table 1 ) represented B10 and B14% for NM and M groups, respectively. These sequences could result from either unexpected contaminating nucleic acids or transcripts from mutated regions of the CLL genome not yet reported. A significant proportion of small fragments matching either sense or antisense strands of the human genome but unable to form hairpin structures with flanking sequences were classified as noncoding RNA transcripts and represented 12 and 19% for the NM and the M group, respectively. Sequences matching the human genome with flanking sequences able to form typical hairpin structures that were not registered in the miRBase of the Sanger Institute (http://microrna.sanger.ac.uk/sequences/ search.shtml) were classified as novel miRNA candidates. From pooled samples of NM CLL cells, we have identified 24 clones corresponding to 7 known human miRNAs ( Table 2) . From pooled samples of M CLL cells, we have identified 32 clones corresponding to 11 previously reported human miRNAs. Overall, 13 known miRNAs contributed to all of the cloned miRNAs from both groups of samples. Most miRNAs were exclusively cloned from only one group of samples or were cloned with different frequencies, suggesting a different signature distinguishing between NM and M groups of samples. Of note, miR-22, miR-24, miR-26a, miR-29a and miR-142-5p were only cloned from M CLL cells. In contrast, miR-30d and miR-191 were only cloned from NM CLL cells. Although this asymmetric distribution of mature miRNAs suggested a different profile of miRNA expression between the NM and M group of samples, it should be taken into account that the library is not close to saturation.
Differential miRNA expression profile in normal and leukemic B cells
The expression profile of miRNAs cloned from CLL samples and other miRNAs reported as relevant in normal and malignant B-cell differentiation 35 were evaluated by northern blot and compared with the expression levels in normal peripheral CD19 þ B cells obtained from pooled samples of four healthy donors. As depicted in Figure 1 , northern signals of samples from representative CLL patients from both prognostic groups revealed that most miRNAs were expressed at lower levels than those seen in normal B lymphocytes suggesting a reduced accumulation of mature miRNAs in leukemic B cells with the exception of miR-16 and miR-191 for the NM CLL group and of miR-29a for the M CLL group. However, northern blot data revealed that miR-142, miR-191, miR-15a, miR-16 and miR-29a were differentially expressed between NM and M CLL samples. The only miRNA overexpressed in CLL cells when compared to normal B cells was miR-155.
Low levels of miR-181a, miR-30d and let-7a expression in CLL cells Next, we analyzed the expression profile of some known miRNAs, recently reported to play important roles in normal Sequences that did not match with any known human sequence from public databases. mouse and human hematopoiesis, particularly during B-and T-lymphocyte lineage differentiation and in B-cell lymphomas. 35, 36 In this respect, miR-181a is expressed in bone marrow progenitor cells and is upregulated in mature B lymphocytes. 35 Furthermore, miRNA let-7 was shown to be conserved broadly in many animal species with higher levels in differentiated normal cells and to be decreased in tumoral undifferentiated cells. 20, 37 Interestingly, northern blots clearly revealed a significant decrease in let-7a expression together with virtual absence of miR-181a expression in all samples from CLL patients independently of the mutational status of V H genes ( Figure 1 ). As expected, neither normal B lymphocytes nor CLL samples expressed miR-223, which was reported to be confined to myeloid lineage cells. As judged by these results CLL cells could represent a less differentiated state than normal B cells in contrast to the classical view of mature and phenotypically activated cells. The expression levels of the respective precursors of miR-181a, miR-30d and let-7 were assessed by quantitative RT-PCR in order to distinguish between decreased transcription and impaired processing into mature miRNAs (Figure 2 ). Primers were designed to flanking regions of predicted precursors and therefore identify precursors as well as primary transcripts of the respective miRNAs. Results depicted in Figure 2 show that primary transcripts and/or precursors of miR-181a, miR-30d and let-7a are all expressed at higher levels than precursors of other reference miRNAs precursors having levels of mature miRNAs similar to normal B cells. This data suggest that the observed decrease of mature miR-181, miR-30d and let-7a could be explained by impaired processing of precursor molecules leading to their intracellular accumulation and/or impaired nuclear export of pre-miRNAs. 38 Novel miRNA candidates cloned from leukemic CLL cells
As depicted in Tables 1 and 2 , we have cloned five not previously described miRNA candidates from CLL samples. These novel miRNAs (Table 3) were identified and mapped to the human genome in public databases by blast sequence analysis (http://www.ncbi.nlm.nih.gov/Genbank/index.html). Analysis of secondary structures was performed using the online version of the Vienna RNA package software in order to identify hairpin structures typical for miRNA precursors (http://rna.tbi. univie.ac.at/cgi-bin/RNAfold.cgi/). Their potential to be miRNA Figure 1 Expression levels of selected mature miRNAs in CLL cells relative to normal CD19 þ B lymphocytes. Expression levels were assessed by northern blot assays from total RNA isolated from leukemic cells and normal peripheral B lymphocytes. Samples from CLL patients were segregated into unmutated (three representative patients) and 'mutated' (four representative patients) according to the mutational status of IgV H genes. 5S rRNA detected by ethidium bromide staining of gels was used as loading control. Since normal B CD19 þ lymphocytes were negative for miR-223, a control RNA from peripheral mononuclear cells were used as normal control (peripheral blood mononuclear cells, PBMC) to assess expression of this miRNA in CLL patients. Figure 2 qRT-PCR analysis of miRNA precursors expression. The relative amount of each precursor miRNA to the reference 5S rRNA gene was expressed as n-fold variation of miRNA levels in test samples (CLL cells) with respect to samples from normal CD19 þ B cells. Error bars represent the standard error of the mean obtained from triplicates samples.
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precursors was scored and validated by using the online structure-based miRNA tool (http://tagc.univ-mrs.fr/mirna/). 39 One of these novel miRNAs originated from the 3 0 arm of the let-7i precursor and cloned from M samples whose expression has been recently included in the miRBase of the Sanger Institute (release 10 August 2007) as hsa-let-7i*. Interestingly, three other miRNA were cloned in samples from M leukemic cells and all mapped to intronic regions of engulfment and cell motility 1 gene (miR-1200), the cyclin B1 interacting protein 1 isoform b (miR-1201) and to a poorly characterized transcription unit with three splice sites (miR-1202). The only candidate isolated from NM samples (miR-1203) was also located in an intron of the SCAP1 protein (src family-associated phosphoprotein 1). Of note, this is a cytoplasmic protein belonging to the src family kinases, preferentially expressed in T-lymphocytes and known to interact with p59fyn. To analyze the relevance in CLL pathogenesis of these novel miRNA candidates we searched for their putative mRNA targets by using public online algorithms as described above. We selected the best 10 scores obtained with miRanda (Table 4 and Supplementary Table 1) . Although the top 10 target mRNA obtained mapped essentially into human chromosomes 1 and 2, most of them surprisingly mapped within a small region in the short arm of chromosome 1 (1p31 to 1p36) known to display extremely common genetic lesions in human cancer of epithelial, neural and hematopoietic origin. 40 Interestingly, several of these highly scored targets contained predicted miRNA sites in their 3 0 -UTR which were shared by two or more of the novel miRNAs described here (Table 4) . These shared targets included the chromodomain helicase DNA-binding protein 5 CHD5, hairy/enhancer of split, Drosophila homologs 2 and 3 (HES2 and HES3) and positive regulatory (PR) domain-containing protein 16 (PRDM16) among others. Most of these genes have been predicted to function either directly or indirectly as tumor suppressors. A complete list of targets and the respective scores are depicted in Supplementary Table 1 . Further analysis of predicted targets was performed using the local version of TargetScan (Supplementary Table 3) . Interestingly, when evolutionary constraints were removed, several targets were found to be predicted by both algorithms. Supplementary Table 2 depicts these results and includes CHD5 with three predicted sites for the miR-1202 and PRMD16 with four predicted sites for the miR-1203.
Discussion
In this work we have compared the expression profile of cloned small RNAs from purified CLL cells to that of normal CD19 þ B lymphocytes by northern blot assays. According to the mutational status of IgV H genes combined to another parameter of prognostic significance as ZAP-70, CLL samples were segregated into two groups with well-recognized different prognostic and clinical outcome. In normal tissues, about 25 to 40% of cloned small RNAs correspond to miRNAs. 19, 41 In the case of CLL, miRNAS represented about 10 % of small RNAs and included a total of 13 known miRNAs. This is in agreement with previous reports indicating a reduced accumulation of miRNAs in neoplastic tissues, 19, 42 which was associated with an impaired processing of miRNA precursors. In a second step the expression level of miRNAs was assessed by northern blot. Our results showed that most miRNAs from CLL B cells display reduced levels of expression when compared to normal CD19 þ B cells. Interestingly, this was not due to a reduced transcription of precursor miRNA (including pri-and pre-miRNAs), since our real-time PCR results revealed the accumulation of precursor species. In this respect, previous reports have shown that Table 3 Novel miRNA candidates cloned from CLL cells Abbreviation: miRNA, microRNA. a The hairpin score was calculated according to structural features of predicted hairpins using the online structure-based miRNA tool (http://tagc.univ-mrs.fr/mirna/). 40 Scores under 50 are considered inadequate substrates for RNAse III-dependent processing.
mammalian miRNAs can be regulated at the level of miRNA processing. 43 In addition, a widespread downregulation of miRNAs in cancer resulting from a failure in the maturation step was recently demonstrated. 44, 45 The highly stringent conditions to gain specificity in our northern blot assays have not allowed us to study accumulation of the respective precursors. However, the kinetics of export/processing of different miRNAs and/or differential turnover of mature miRNAs cannot be excluded.
Therefore, the causes of decreased miRNAs in CLL cells remain unsolved and will require additional work. As shown in Table 2 , only 7 of the 13 miRNAs found in CLL B cells were observed in NM CLLs, whereas 11 out of these 13 were found in M patients. Two were exclusively cloned from NM patients (miR-30d and miR-191), six from M patients miRNAs (let-7i, miR-22, miR-24, miR-26a, miR-29a and miR-142-5p) and five were shared by both groups (miR-15a, miR-16, miR-142-3p, miR-150 and miR-155). Although these results need to be substantiated in a larger number of patients, they suggest a differential profile of miRNA expression in the two prognostic groups of CLL patients. Fulci et al.
28 using a cloning-based approach reported that miR-150, miR-29b, miR-29c and miR-223 were cloned at higher frequencies in cells from patients with the M phenotype. By using a micrroarray-based approach to analyze expression levels of different known miRNAs, Calin et al. 27 have recently identified a set of 13 miRNAs differentially expressed in CLL patients according to the mutational status of IgV H genes and ZAP-70 expression. A majority of the miRNAs reported as differentially expressed in CLL prognostic groups by these reports were also found in our study. However, our results report for the first time the expression of miR-22, miR-24, miR26a and miR-142-5p in the M group and of miR-30d and miR-191 in the NM one. To gain further insight into the expression levels of different miRNAs, we compared CLL B cells to normal CD19 þ B cells by northern blot for the expression levels of representative cloned miRNAs, as well as a number of miRNAs recently reported to play important roles in normal mouse and human hematopoiesis, particularly during B-lymphocyte lineage differentiation and in B-cell lymphomas. 35, 46 Our results showed that with the exception of miR-155, all miRNAs were underexpressed in CLL samples irrespective of the mutational status of IgV H genes. These results are in agreement with those reported by Fulci et al., 28 but we failed to demonstrate miR-21 and miR-150 overexpression or a differential expression of miR-223. Our data are in complete concordance with reports from Croce's group showing that miR-15 and miR-16 were downregulated in good prognosis patients, while miR-29 was downregulated in bad prognosis group patients. 27 Interestingly, when compared to normal CD19 þ B cells, CLL cells constantly exhibited a virtual absence in the expression of miR-181a and very low levels of miR-30d and let-7a regardless of the mutational status of V H genes and ZAP-70 expression. The miR-181a was initially cloned by Dostie et al. 47 from the human retinoblastoma Weri cells. A recent report 35 revealed that miR181a was preferentially expressed in thymocytes and Blymphoid cells and commits hematopoietic precursors cells to the B-cell lineage, suggesting that miR-181a is a positive regulator of B-cell differentiation in normal hematopoiesis. 25 The miR-181a is also strongly upregulated during skeletal muscle-cell differentiation in mammals and participates in establishing the muscle phenotype through downregulation. 48 In addition, Neilson et al. 30 reported a significant upregulation of miR-181a in DP thymocytes which confers repression through the 3 0 -UTR of relevant targets, including Bcl-2 and T-cell antigen receptor-a chain. In this respect, most CLLs have been reported to contain high levels of the antiapoptotic protein Bcl-2, 6 and it has been recently reported that upregulation of this antiapoptotic protein in CLL is the consequence of miR-15a and miR-16-1 deletion or downregulation because these miRNAs negatively regulate Bcl-2 through 3 0 -UTR sites. 30 However, in a recent report downregulation of miR-15a and miR-16 did not parallel any significant increase in Bcl-2. 28 According to these reports, significantly decreased levels of miR-181a in CLL cells could result in overexpression of the Bcl-2 antiapoptotic protein and since this miRNA is involved in terminal B-cell differentiation its overexpression in CLL B cells could suggest that these cells do not parallel normal CD19 þ B lymphocytes and represent a more undifferentiated phenotype. Although Calin et al. reported miR-181 overexpression in CLL cells, 27 this may be accounted for by the fact that the microarray method used by this group includes both the precursor and mature forms of this molecule. In agreement with our results an exhaustive analysis of Fulci's data 28 revealed that miR-181a was never cloned in samples from nine CLL patients. Thus, miR-181a deregulation may play a role in some phenotypic features of CLL B cells, such as Bcl-2 overexpression.
We also reported a significant decrease in expression levels of let-7a and miR-30d. Originally observed in Caenorhabditis elegans, let-7a is one of the founding members of the miRNA family 49 and is highly conserved in animals from worms to humans. 37 The highest levels of let-7a expression occur in differentiated adult tissues 37, 50 and inappropriate expression of let-7a results in oncogenic loss of differentiation. Currently, let-7 is considered as a tumor suppressor gene 20 since reduced expression levels of let-7 were frequently found in both in vitro and in vivo lung cancer studies. In addition, let-7 negatively regulates the key oncogenes Ras and Myc by targeting their mRNAs for translational repression, 25 highlighting its role in cancer pathogenesis. MiR-30d was formerly cloned from mouse liver, and its expression was reported in CD5 þ and CD5À normal B lymphocytes, although its biological significance remains unknown. 28, 29 Additionally, we report four novel miRNA candidates from CLL cells with M phenotype and one from those with an NM phenotype. Although these candidates need further confirmation to be definitively assigned as new miRNAs, the structure-based scoring of these miRNAs by using the recently described algorithm by Ritchie et al. 39 reveals that at least four out of five precursor hairpins fit requirements of true pre-miRNAs.
Surprisingly, a significant proportion of these mRNA targets mapped within a small region in the short arm of human chromosome 1 (1p31-1p36). This region is frequently deleted in human cancers of epithelial, neural and hematopoietic origin. 40 Initially reported in neuroblastoma, 51 it is also deleted in hematopoietic malignancies, including acute myelogenous leukemia, 52 chronic myelogenous leukemia 53 and lymphoma 54 These data suggested that one or more tumor suppressor genes mapping into 1p36 are lost or inactivated in a variety of human cancers. The recent description in this region of CHD5 as a new tumor suppressor in human cancer threw light on this issue. 40, 55 CHD5 appeared as a target shared for miR-1201, miR-1202 and miR-1203. Interestingly, PRDM16, Wnt3 and Hes genes are predicted targets that map into the same region of human chromosome 1p36 and also appear to constitute shared targets for these same novel miRNA (Table 4 and Supplemental Table  1 ). CHD5 belongs to a chromodomain superfamily, including a large number of proteins with chromatin organizing modulator (chromo) domains 56 characterized by helicase/ATPase-and DNA-binding domains. In a recent report Bagchi et al. 40 demonstrated that CHD5 acts as a tumor suppressor that controls proliferation, apoptosis and senescence via the p19
Arf / p53 pathway. Thus, downmodulation of CHD5 in CLL mediated by these novel miRNAs could predispose to malignancy by crippling tumor-suppressive pathways involving p16
Ink4a
, p19
Arf and p53, providing a new underlying mechanism for initiating tumorigenesis in CLL.
The PRDM16 (PR domain-containing protein 16) defines a subfamily of zinc finger proteins that appear to function as negative regulators of tumorigenesis and includes the myelodysplastic syndrome (MDS) gene inactivated in myeloid leukemia, the PRDM1 transcription repressor of c-myc involved in driving B-cell differentiation and the PRDM2 (RIZ gene) which encodes proteins capable of binding to the retinoblastoma tumor suppressor protein. 57 The PRDM16 gene was demonstrated transcriptionally activated in a subset of MDS and acute myeloid leukemia bearing the t(1;3)(p36;q21) translocation. 58 Recent microarray analyses have demonstrated that the Wnt3 gene is overexpressed in NM CLLs. 59, 60 Additionally, the Wnt signaling pathway was reported to be activated in CLL 61 The Wnt gene family consists of structurally related genes encoding secreted signaling molecules that have been implicated in hematopoietic stem cell homeostasis, hematopoiesis, early B-cell growth and survival, oncogenesis and in several developmental processes, including regulation of cell fate and patterning during embryogenesis. 62 The Hes3 gene belongs to a family of transcription factors with basic helix-loop-helix described initially in Drosophila 63 by acting as primary Notch effectors and by critically influencing cell proliferation, differentiation and apoptosis in metazoans. 64 Hes3 was demonstrated essential to neurogenesis, myogenesis, hematopoiesis, sex determination and maintenance of stem cells, 65 though its implication in tumorigenesis remains elusive. The run-related transcription factor 3 belongs to a family of transcriptional regulators mapping into 1p36 which appeared as another relevant target in hematopoiesis and cancer. 66 These transcription factors are important regulators of lineage-specific gene expression and are bifunctional, acting both as activators and repressors of tissue-specific target genes. 67, 68 Inappropriate levels of RUNX activity were associated with leukemia, autoimmune disease and various solid tumors. 69 Thus, experimental confirmation of the involvement of these putative targets including several tumor suppressors could provide new avenues for exploring innovative pathways in CLL biology and therapy.
Overall, our results provide new data concerning miRNA deregulation in CLL. By using a cloning approach combined with northern blot assays we have confirmed and extended previous reports dealing with an miRNA signature in CLL as well as their ability to discriminate between patients with different clinical outcomes. We also describe for the first time a consistent underexpression of miR-181a, miR-30d and let-7a in CLL B cells when compared to normal CD19 þ B cells. According to previous reports and the predicted or experimentally validated targets, these miRNAs could play relevant roles in initiation and progression of CLL. Whether the consistent underexpression of miRNA 181a is involved in overexpression of the Bcl-2 protein and/or could suggest that the CLL B lymphocyte is an immature B cell remain unsolved issue and point to the difficulty in assigning a normal counterpart to the CLL B lymphocyte. Finally, we report five novel miRNA candidates whose potential targets could be relevant in cancer and CLL pathogenesis. Work in progress in our laboratory aims to extend these data and to experimentally validate the potential targets of these new miRNA candidates.
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